Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Omega Dia LSE:ODX London Ordinary Share GB00B1VCP282 ORD 4P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.50p -3.64% 13.25p 181,979 09:00:55
Bid Price Offer Price High Price Low Price Open Price
13.00p 13.50p 13.75p 13.25p 13.75p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 13.55 -6.91 -0.40 16.8

Omega Diagnostics (ODX) Latest News (4)

More Omega Diagnostics News
Omega Diagnostics Takeover Rumours

Omega Diagnostics (ODX) Share Charts

1 Year Omega Diagnostics Chart

1 Year Omega Diagnostics Chart

1 Month Omega Diagnostics Chart

1 Month Omega Diagnostics Chart

Intraday Omega Diagnostics Chart

Intraday Omega Diagnostics Chart

Omega Diagnostics (ODX) Discussions and Chat

Omega Diagnostics Forums and Chat

Date Time Title Posts
10/12/201814:59Omega Diagnostics - nicely poised for significant growth979
01/8/201707:17Omega Diagnostics1,774

Add a New Thread

Omega Diagnostics (ODX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
13:40:0013.402,164289.98O
13:01:2113.0050,0006,500.00O
12:15:4013.5029,8154,025.03O
10:48:4913.50100,00013,500.00O
View all Omega Diagnostics trades in real-time

Omega Diagnostics (ODX) Top Chat Posts

DateSubject
10/12/2018
08:20
Omega Diagnostics Daily Update: Omega Dia is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker ODX. The last closing price for Omega Diagnostics was 13.75p.
Omega Dia has a 4 week average price of 13.25p and a 12 week average price of 13.25p.
The 1 year high share price is 21.75p while the 1 year low share price is currently 8p.
There are currently 126,959,060 shares in issue and the average daily traded volume is 304,104 shares. The market capitalisation of Omega Dia is £16,822,075.45.
07/12/2018
17:56
barrywhit: buywell3, the market was expecting/hoping to see some projected sales figures for CD4 but they probably wont be available until Feb/March time after the Nigeria meeting/evaluation....then hopefully the share price will improve....
07/12/2018
15:34
rivaldo: Big interview with the CEO - I'll paste it in full if you don't mind as access to the Herald's content is limited to only two articles per month. Note that the CD4 update is coming within a month or so: Https://www.heraldscotland.com/business_hq/17272806.shares-drop-14-as-omegas-hiv-test-guidance-delayed/ " Colin King, Omega chief executive, above, said: "Our results are where we expected them to be. "Obviously over the last six months we’ve gone through a period of restructuring the business. "I’m pleased with how that’s going, and once we get that clear it allows us to completely focus on our key growth areas, which are food, allergy and our CD4 test. "In terms of progress in those three areas, again I’m pleased with the progress we are making. "Where we do expect to see significant revenue uplift is with CD4. "In terms of CD4, we have two products, the 350 test which is used as a gatekeeper for starting treatment for HIV patients. "We are targeting the countries where we believe that test will be adopted." Read more: Scottish biotechnology firm hails progress made with HIV test Progress is being made in Nigeria and Zimbabwe. He added: "Both countries are in the process of doing an in-country evaluation and we expect them to be completed during January or February time, so we expect the first commercial order for CD4 to Nigeria in February or March, so that is great news. "At this stage we had hoped to give a bit of guidance on what that would look like. "Unfortunately we don’t have that just yet - we are still running through that with our partner. "There is a key meeting next week in Nigeria and we will get a better feel for what that will look like when our meeting is concluded. "But we do expect it to be significant for us. "Where we see the higher potential is in the advanced disease test (the second CD4 product) that we are developing. "Overall we are making good progress there." He said: "Probably the biggest challenge is where you can’t fully control your own destiny where you are working with other countries and they have to go through in-country evaluations, you always wish these things would go quicker than they do. "They will happen, it is just more a case of timing that is probably the biggest frustration there." He added: "I’m obviously speculating but my impression is that the markets were expecting us to guide on CD4 and obviously we haven’t given guidance there so there may be a little bit of disappointment on not guiding on CD4 but clearly what we want to do is when we do guide we get the numbers." "By Christmas or early New Year we hopefully will be giving that guidance and hopefully that will get the share price back up again." Kieron Harbinson, Omega finance director, said: "The overall message is that we’ve re-shaped the business, we are a leaner outfit and we’ve got three key product areas to focus on that can deliver growth." Analysts at house broker FinnCap said the interim results were "in line with the October trading update, albeit complicated by the disposal of its legacy infectious diseases business, closure of loss-making German and Indian operations and exceptional profits/write-backs" and made no changes to its full year forecast which assumes an adjusted pre-tax profit of £200,000 in the second half."
02/11/2018
15:51
hyperboreus: I was beginning to think the same barry but 2 x 50,000 sells this afternoon would suggest otherwise, not wishing to put the mockers on things here but I do agree with rivaldo that the current share price of 16.5p is remarkable in the current market given where it was at the end of June. Interesting to note that on further investigation one of the 3 vacancies currently advertised is for a Product Marketing Manager for the Food Intolerance Business based in Littleport Cambs Food Intolerance Testing (FIT) will be responsible for managing marketing programs and strategies for the Food Intolerance product offering of Cambridge Nutritional Sciences (CNS). He/She will work closely with Sales & Marketing, R&D, Regulatory, Omega global distributor network and other sales outlets to ensure the Food Intolerance product portfolio is correctly positioned in the diagnostic marketplace for growth and sustainability. That possibly put the nail in the coffin of my theory that they are likely to flog it off anytime soon but we shall see!
27/9/2018
10:10
rivaldo: Great to see the share price move up nicely on relatively small buying. Perhaps not much stock around/Sneller is mopping it all up. Today's news will help to encourage the market that at last ODX can deliver on its promises, especially with the first IDS purchase order.
18/7/2018
19:45
barrywhit: Mainly sells today, last year that RNS would have sent the share price 2p higher, now we have no P.I's so a few traders taking a profit.....
21/5/2018
07:23
barrywhit: The trouble is they have lost most of their P.I's hence the lack of trades this morning. It is P.I's that move the share price not Institutions or Directors they only buy when the share price is struggling or Placings....They will need to start to show increased sales figures to attract new investors imho...
24/4/2018
21:11
p1nkfish: I will keep a runt of shares for general interest. When you feel deceived by management it doesn't matter what subsequently happens to the share price. Trust is gone. For how long have we been led to believe ODX management was competent? Even down to selling German property to lease back to fund "growth". I thought they were being careful with news to cool down any speculation. Fact is they didn't have much to shout about and were keeping stum so suckers like me couldn't work out they were winging it. Sneller is trapped, where is he going to off-load his stock except in a wind down? He made mistakes on PIM, hope it doesn't repeat here. Mills is an excellent value man and speculator. I doubt this is a conviction buy for him else he would be closer to 20% imho. Management will be instructed what to do and hopefully will execute accordingly and not acquire delusions of competence along the way. I hope you all make a packet from this.
20/4/2018
20:51
hyperboreus: Well usually I agree with you p1nkfish but not on this occasion however as I would never ever trust any organistation that issues a trading update at close of play on a Friday afternoon, absolute shysters from my standpoint. It would appear to me that Immunodiagnostic Systems or IDS as they like to call themselves are about as clueless and trustworthy as our lot, no wonder it took nearly 18 months to sort the so called distribution agreement out. Anyhow that non event is really irrelevant to me now as it would appear the most pertinent happening today is the volume of 10,320,600 shares traded equating to around 8% of total shares in issue, which I do not believe I have seen whilst I have been an ODX shareholder during the past 6 years. The ODX RNS clearly has very little to do with the rise in share price but the 4.5 million x 2 trades @ 08:39hrs followed by the 0.5 million @ 08:58hrs this morning are intriguing. It is all conjecture until a formal announcement is made but I would think and longingly hope that an external third party has taken an interest in proceedings here. Hopefully the 'Balls Up Investor Presentation Jobby' on 21 May 2018 when no new information will be disclosed will not be necessary as Messrs King, Harbinson & Grewal will looking for alternative employment! Have a great weekend 😝
06/4/2018
10:53
hyperboreus: Another 8 months away yet but Messrs Evans, Shepherd and Harbinson each have options granted on 10 December 2008 with an exercise price of 19p which expire on 10 December 2018. No idea what is likely to propel the share price north of 19p in the short term, just shows how their expectations of how Omega would perform over the last 10 years have just not materialised. In a perverse way I almost hope that the share price doesn't rise too much this year as they do not deserve to profit from them in my opinion, that is my 'gripe of the day' out of the way now! 😧
23/1/2017
16:12
hyperboreus: Looking like you might get your wish longshanks re 16.5p Been having a really in depth look at all the director share options and the first tranche issued to Evans, Shepherd and Harbinson with exercise price at 19p expire on 10 December 2018 having been issued on 10 December 2008. I am sure they would have been expecting ODX's share price to be much higher by now over 9 years later as it has gone nowhere really since then. The next sizeable batch issued to Shepherd, Harbinson and Grewal with exercise price at 14.5p expire on 5 July 2022 but share price must be 25p or higher. Interestingly David Evans doesn't have any other options other than the one which expires next December, but having said that he was very generously 'allowed' to purchase 2,760,134 shares at 12p on 17 Dec 2010 in a private placing in relation to the purchase of the ALLERGOPHARMA IVD BUSINESS. His average share price purchase by the way is 12.81p, Jag Grewal's is 19.92p, not so easy to work out Harbinson's and Shepherd's as they they were directors in ODX before reverse takeover in 2006 but my best guess for Harbinson is 12.88p and 9.38p for Shepherd. My average share price in ODX has gone up significantly from my first purchase in April 2012 at 10.25p but at just over 16p I am still confident that exciting times are ahead, just not sure how long I might have to wait like the rest of us!
Omega Diagnostics share price data is direct from the London Stock Exchange
Your Recent History
LSE
ODX
Omega Diag..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20181210 19:45:23